NasdaqGS:BBIOBiotechs
What BridgeBio Pharma (BBIO)'s Surging 2025 Revenue and Growing Losses Means For Shareholders
BridgeBio Pharma, Inc. has reported its fourth-quarter and full-year 2025 results, with Q4 revenue rising to US$154.18 million from US$5.88 million a year earlier and full-year 2025 revenue reaching US$502.08 million, while the company’s annual net loss increased to US$724.93 million and basic loss per share from continuing operations was US$3.78.
Management framed these results as a turning point, highlighting accelerating commercial traction for ATTR-CM drug Attruby and multiple positive...